Eltrombopag in Treating Post‐Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug Tapering
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70081 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Rawan Al-Omari und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada. Hauptthemen laut MEDLINE: Hydrazines, Benzoates, Pyrazoles, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
The utilization of eltrombopag (EPAG) in the management of post allogenic hematopoietic cell transplant (HCT) cytopenia has exhibited promising outcomes. Isolated thrombocytopenia and poor graft function (PGF) are factors that adversely influence transplant outcomes and patient well‐being. This retrospective study aims to assess EPAG efficacy in this context as a primary outcome and evaluate early EPAG tapering post complete response (CR) for cost efficiency and response durability as a secondary outcome. We analyzed 39 patients who underwent allogeneic HCT; EPAG was administered to 89.7% of patients for PGF and 10.3% for isolated thrombocytopenia. The overall response rate (ORR) after 4 weeks of EPAG treatment was 71.8%, with 48.7% achieving a complete response (CR). Early tapering of EPAG post‐CR was explored for cost benefit among responders. Early tapering was defined as the start of tapering after 4 weeks of achieving CR and was found to be associated with significant response durability with a trend towards cost effectiveness. Eltrombopag response was independent of megakaryocyte number or density prior to drug initiation. The study suggests EPAG as a safe treatment for PGF and isolated thrombocytopenia post‐allogeneic HCT and proposes early drug tapering as a potentially cost‐beneficial approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada.
- Transplantation and Cellular Therapy Program, Ottawa Hospital, Ottawa, Canada.
- Department of Pathology, Princess Margaret Cancer Centre, Toronto, Canada.
- Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada.
ORCID-Profile: Rawan Al-Omari, Ram Vasudevan Nampoothiri, Ivan Pasic, Rajat Kumar
Zitieren
APA
Al-Omari, R., Nampoothiri, R. V., Sakhdari, A., Atenafu, E. G., Chiarello, C., Kim, D. D., Law, A., Pasic, I., Novitzky-Basso, I., Viswabandya, A., Michelis, F. V., Mattsson, J., & Kumar, R. (2026). Eltrombopag in Treating Post‐Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug Tapering. European Journal of Haematology. https://doi.org/10.1111/ejh.70081
Vancouver
Al-Omari R, Nampoothiri RV, Sakhdari A, Atenafu EG, Chiarello C, Kim DD, et al. Eltrombopag in Treating Post‐Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug Tapering. European Journal of Haematology. 2026. doi:10.1111/ejh.70081
BibTeX
@article{AlOmari2026,
author = {Al-Omari, Rawan and Nampoothiri, Ram Vasudevan and Sakhdari, Ali and Atenafu, Eshetu G and Chiarello, Caden and Kim, Dennis D and Law, Arjun and Pasic, Ivan and Novitzky-Basso, Igor and Viswabandya, Auro and Michelis, Fotios V and Mattsson, Jonas and Kumar, Rajat},
title = {Eltrombopag in Treating Post‐Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug Tapering},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70081}
}
EUVIMED